1630041-31-4

Basic information

• Product Name: C₂₇H₂₂F₆N₂O₂
• Synonyms: C₂₇H₂₂F₆N₂O₂
• CAS NO: 1630041-31-4
• Molecular Weight: 520.474
• Mol File: 1630041-31-4.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: C₂₇H₂₂F₆N₂O₂(CAS DataBase Reference)
• NIST Chemistry Reference: C₂₇H₂₂F₆N₂O₂(1630041-31-4)
• EPA Substance Registry System: C₂₇H₂₂F₆N₂O₂(1630041-31-4)

Safety Data

• Hazardous Substances Data: 1630041-31-4(Hazardous Substances Data)

Upstream product

• 673-22-3 2-Hydroxy-4-methoxybenzaldehyde 
• 95-01-2 2,4-Dihydroxybenzaldehyde 
• 73790-20-2 4,4'-bis(trifluoromethyl)benzil 
• 107811-48-3 2-isopropoxy-4-methoxybenzene-1-carboaldehyde 

Downstream Products

• 1630041-48-3 N,N-diethyl-2-(2-(2-isopropoxy-4-methoxyphenyl)-4,5-bis(4-(trifluoromethyl)phenyl)-imidazol-1-yl)-ethanamine 
• 1630041-46-1 1-(3-(2-(2-isopropoxy-4-methoxyphenyl)-4,5-bis(4-(trifluoromethyl)phenyl)-imidazol-1-yl)propyl)piperidine 
• 1630041-47-2 4-(3-(2-(2-isopropoxy-4-methoxyphenyl)-4,5-bis(4-(trifluoromethyl)phenyl)-imidazol-1-yl)propyl)morpholine 

Relevant articles and documents

Design, synthesis and biological evaluation of 2, 4, 5-triphenylimidazole derivatives with preliminary SAR

A series of N1-substituted 2,4,5-triphenyl imidazole derivatives was designed, synthesized and evaluated for their p53-MDM2 binding inhibitory activities and anti-proliferative activities in vitro against four human cancer cell lines (PC3, KB, A549 and HCT116). Although logical evaluation revealed weak p53-MDM2 binding inhibitory activities, most of the obtained molecules displayed moderate to potent cytotoxicities against tested cell lines. As a potential lead compound for further optimization, compound 9c was evaluated as the most potent compound against four cell lines and could induce cell cycle arrest at G2/M phase. The binding mode of compound 9f and MDM2 was further studied by docking analysis and the unexpected interaction mode revealed that this series of compounds may take part into a different binding modes as the lead compound Such as Nutlin, which could induce a different mechanism in cancer therapy.